Repligen Corporation
RGEN
Positions held
Your positionsRGEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Repligen Corporation operates in a growing healthcare sector, focusing on bioprocessing technologies, which are essential for the production of biologics and have a strong demand due to the increasing need for biopharmac
- Revenue increased by 5% compared to the prior quarter, reaching $204 million.
- The company maintains a solid gross margin of 53.9%, although it slightly decreased from 55.7% in the previous quarter.
- Despite its strong market position, Repligen faces challenges with earnings growth, which has seen a decline of 65.9%.
- The trailing P/E ratio stands at 239.53, indicating that the stock may be overvalued compared to its earnings.
- Net income dropped to $5.008 million in the latest quarter, down from $8.333 million in the previous quarter.
Fundamentals
| Market cap | $10.40B | Enterprise value | $9.13B | Trailing P/E | 224.44 | Forward P/E | 61.88 |
| PEG | 1.67 | Price / book | 4.38 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | 11.9% | Earnings growth | -65.9% | Gross margin | 53.8% | Operating margin | 9.3% |
| Profit margin | 5.3% | ROE | 2.0% | ROA | 1.4% | Debt / equity | 0.33 |
| Current ratio | 9.05 | Free cash flow | $113.42M | Analyst recommendation | strong_buy | Mean target | $196.70 |
| 52w high | $198.87 | 52w low | $100.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $204M | $194M | $198M | $189M | $182M | — |
| Op margin | 9.3% | 8.9% | 8.3% | 6.7% | 4.5% | — |
| Net income | $5.0M | $8.3M | $13.3M | $14.9M | $14.9M | — |
| Gross margin | 53.9% | 55.7% | 52.5% | 53.2% | 51.0% | — |
| Gross profit | $110M | $108M | $104M | $101M | $93.0M | — |
| Operating income | $19.0M | $17.3M | $16.3M | $12.7M | $8.1M | — |
- Revenue +5% vs prior quarter ($204M vs $194M).
- Gross margin 53.9% (was 55.7% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $738M | $634M | $632M | $802M |
| Op margin | 5.6% | -5.0% | 2.7% | 24.4% |
| Net income | $48.9M | -$25.5M | $35.6M | $186M |
| Gross margin | 52.3% | 43.3% | 44.0% | 56.9% |
| Gross profit | $386M | $275M | $278M | $456M |
| Operating income | $41.6M | -$31.9M | $17.1M | $196M |
Headlines — watch
• [WARN · legal] 3 Unpopular Stocks Walking a Fine Line
News
2026-10-06 · Why Are Freshworks (FRSH) Shares Soaring Today
2026-10-06 · Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing
2026-10-06 · Repligen Closes BioLife Solutions Acquisition
2026-10-06 · Repligen Completes Acquisition of BioLife Solutions
2026-10-05 · Freshworks Set to Join S&P SmallCap 600
2026-10-05 · Freshworks stock climbs on S&P SmallCap 600 inclusion
2026-10-05 · BioLife Solutions Shareholders Approve Repligen Merger Agreement
2026-10-02 · 3 Healthcare Stocks That Concern Us
2026-09-29 · Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
2026-09-25 · Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
2026-09-23 · AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
2026-09-23 · 3 Unpopular Stocks Walking a Fine Line
Price (daily)
Full chart · RSI · MACD · patterns